Adult Stem Cell Trial Approved By Royal Melbourne Hospital For Orthopaedic Use
Australian adult stem cell company, Mesoblast Limited , announced today approval to commence the first human orthopaedic trial of Mesoblast’s specialist adult stem cell technology.
ViaCell, Inc. Says FDA Formalizes Halting Of Study By Issuing Clinical Hold
ViaCell, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company’s Phase I clinical trial evaluating CB001, an investigational cord blood stem cell product for hematopoietic stem cell transplantation in patients affected by a variety of cancers.
StemCells, Inc. Announces Filing of IND Amendment for Human Neural Stem Cell Transplant Treatment for Batten Disease
StemCells, Inc. today announced the filing with the U.S. Food and Drug Administration (FDA) of an amendment to its initial IND (Investigational New Drug) application to begin a clinical trial of its human neural stem cells (HuCNS-SC) as a treatment for Batten disease.
Stem Cell Therapy International Signs Exclusive License Agreement for the Supply of Stem Cells and Use of 26 Related Patents from the Institute of Cell Therapy In Kiev, Ukraine
Stem Cell Therapy International, Inc. today announced that it has signed an exclusive global Licensing Agreement with the Institute of Cell Therapy (ICT) a biotechnology company incorporated and organized in Kiev, Ukraine, for the supply of stem cells and use of 26 related patents.
ReNeuron Group PLC Holds Key Meeting with the FDA Regarding Its ReN001 Stem Cell Therapy for Stroke
ReNeuron Group PLC today announced that it has held a formal pre-IND1 meeting with the CBER2 component of the US Food & Drug Administration (FDA) regarding its lead ReN001 stem cell therapy to treat chronic disability after stroke.
Cellerant Therapeutics Adds $9 Million to Series B Round for a Total of $25 Million
The first closing was led by Novel Bioventures, with the participation of Series A stockholders MPM Capital, Allen & Company LLC, and BD Ventures, and new investors CX Venture Group and Amgen founder George Rathmann.
Genzyme Expands Global Infrastructure for Manufacturing, R&D
Genzyme Corporation announced today that it has substantially strengthened its global infrastructure for manufacturing and product development through four major expansion projects in Belgium, Ireland, and the United Kingdom.
Alnylam Grants QIAGEN License to Kreutzer-Limmer Patents in the Research Products Market
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has granted QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA), a leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins, a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family.
Dendreon Corporation Announces Modulation Of Trp-p8 Significantly Inhibits Tumor Growth In Vivo
Dendreon Corporation today announced new data was presented showing that modulation of the Trp-p8 tumor target with small molecules may represent a new approach to cancer therapy.
Kensey Nash Announces Expanded Indications for Its BioBlanket(TM) Soft Tissue Repair Patch
The expanded indications specifically allow the product to be used for the repair of hernias and reinforcement of soft tissue in rotator cuff repair surgery, two of the important target markets for the technology.
Life Therapeutics Acquires Pyramid Biological Corporation; Acquisition Expands Company’s Plasma Collection Capacity, Increases Share of Global Hyperimmune and Normal Plasma Markets
Life Therapeutics announced today the signing of a binding agreement to acquire privately-held Pyramid Biological Corporation, for US$13 million plus assumption of US$7 million debt. An additional US$5 million is subject to milestones.
Osiris Launches the Osteocel(R) Product Line; Bone repair product provides a much needed option for orthopedic surgery
Osiris Therapeutics, Inc. announced today that it has begun distribution of Osteocel(R) a product indicated for the repair, replacement and/or reconstruction of bone defects. Osteocel is an allogeneic bone matrix containing viable stem cells.
Vernalis PLC Signs Agreement With Diosynth Biotechnology (Research Triangle Park) For Phase III Manufacture Of V10153
Vernalis Plc has signed a contract with Diosynth Biotechnology for process development, scale-up and manufacturing of V10153 for Phase III clinical trials.
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents
Immunotherapy Reports Order Form